ASH is over but its memories are fresh. My strongest impression of the meeting is that multiple myeloma treatment advances continue to be significant at this huge yearly event. Dr. Durie explained there were an amazing 939 abstracts relating to myeloma at ASH this year. At the IMWG (International Myeloma Working Group) meeting, he said […]
If you have not yet noticed, I’m a fan of good music. I’ve had bands since the 70s, growing up with what’s now called classic rock. Funny how time goes by, and it’s now “classic.” I guess it’s a good thing, because I grew up in a time when music had leads and lyrics that […]
December 4, 2018 Before presenting my ASH summary, I’ll mention a late-breaking abstract presentation that I was unable to attend early this morning focused on a phase III trial using Darzalex (daratumumab) in front-line therapy plus Rev-dex versus Rev-dex only for transplant-ineligible patients. The abstract # LBA-2 showed that the addition of Dara decreased the […]
Day 2: A busy day at ASH December 2, 2018 Today I attended oral presentations from 8 a.m. to 6 p.m. with a few short breaks to check out posters and exhibits as well as meet with Pharma companies. Let me discuss several findings from several oral presentations (#abstract). Maintenance Therapy with Ninlaro (Ixazomib)….Tourmaline 3 […]
